Satellos Bioscience Inc Com V.ICO

Primary Symbol: ICOTF

Healthcare Biotechnology

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...

GREY:ICOTF - Post by User

Satellos Bioscience Inc Com

<< Previous

Bullboard Posts

Next >>

Post by allain250on Jul 12, 2018 12:00pm

70 Views

Post# 28306574

Bullous Pemphigoid Pipeline Review H1, Expert Overview 2018

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid – Pipeline Review, H1 2018, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.

Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. The disease can be fatal, particularly in patients who are debilitated. Symptoms include intense itching and burning sensation of the skin. It most commonly occurs in people older than age 60. Treatment includes anti-inflammatory and immunosuppressant.

Report Highlights:-

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

If you want sample copy of the report feel free to reach us @ https://www.industrydataanalytics.com/request-sample-page.php?gturl=bullous-pemphigoid-pipeline-review-h1-2018-gmd00070?source=faircolumnist&mode=02

The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 1 and 3 respectively.

Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Key Companies:-